Literature DB >> 12145334

Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists.

Huey-Jing Huang1, John D Norris, Donald P McDonnell.   

Abstract

Several lines of evidence have indicated that the estrogen receptor (ER) can recruit the corepressors, nuclear receptor corepressor (NCoR) and silencing mediator of retinoid and thyroid receptors (SMRT), to target genes in the presence of tamoxifen, suggesting a possible role for NCoR/SMRT in regulating ER pharmacology. However, a tamoxifen-dependent, direct interaction between NCoR/SMRT and ER in vitro has not been demonstrated. To investigate the possible involvement of different corepressors in the actions of antiestrogen-bound ER, we have constructed a phage display library that expresses 23-amino acid peptides containing the canonical CoRNR box motif in an otherwise random background. Screening of the CoRNR box library with apo-ER or ER treated with tamoxifen or ICI 182,780 led to the isolation of peptides whose ability to interact with ER was influenced by the nature of the bound ligand. Using a series of ERalpha mutants, we found that helix 12 was not required for the binding of CoRNR box peptides, whereas disruption of helixes 3 and 5 had a marked effect on peptide binding. One mutant, ER-L372R, lost the ability to interact with CoRNR box-containing peptides without affecting its binding to LXXLL motif-containing peptides. The estradiol- and tamoxifen-mediated transcriptional activity of ER-L372R was dramatically increased by 11- and 3-fold, respectively, compared with that of wild-type ERalpha. The ICI 182,780-mediated repressional activity of this mutant was also reduced by 4-fold compared with that of wild-type ERalpha. These results suggest that leucine 372 may be an important part of the interaction surface on ER that is responsible for corepressor binding. In addition, our data suggest that corepressors, other than NCoR/SMRT, may be involved in ER signaling.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145334     DOI: 10.1210/me.2002-0089

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  30 in total

1.  Distinct signaling pathways mediate stimulation of cell cycle progression and prevention of apoptotic cell death by estrogen in rat pituitary tumor PR1 cells.

Authors:  Simona Caporali; Manami Imai; Lucia Altucci; Massimo Cancemi; Silvana Caristi; Luigi Cicatiello; Filomena Matarese; Roberta Penta; Dipak K Sarkar; Francesco Bresciani; Alessandro Weisz
Journal:  Mol Biol Cell       Date:  2003-09-05       Impact factor: 4.138

Review 2.  Epigenetic underpinnings of developmental sex differences in the brain.

Authors:  Bridget M Nugent; Margaret M McCarthy
Journal:  Neuroendocrinology       Date:  2011-03-11       Impact factor: 4.914

3.  Delineation of a unique protein-protein interaction site on the surface of the estrogen receptor.

Authors:  Eric H Kong; Nina Heldring; Jan-Ake Gustafsson; Eckardt Treuter; Roderick E Hubbard; Ashley C W Pike
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-23       Impact factor: 11.205

4.  Differential effects of estrogen-dependent transactivation vs. transrepression by the estrogen receptor on invasiveness of HER2 overexpressing breast cancer cells.

Authors:  Mugdha Patki; Marcela d'alincourt Salazar; Robert Trumbly; Manohar Ratnam
Journal:  Biochem Biophys Res Commun       Date:  2015-01-09       Impact factor: 3.575

5.  Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells.

Authors:  Yukun Cui; Airu Niu; Richard Pestell; Rakesh Kumar; Edward M Curran; Yunde Liu; Suzanne A W Fuqua
Journal:  Mol Endocrinol       Date:  2006-04-27

6.  The Dysregulated Pharmacology of Clinically Relevant ESR1 Mutants is Normalized by Ligand-activated WT Receptor.

Authors:  Kaitlyn J Andreano; Jennifer G Baker; Sunghee Park; Rachid Safi; Sandeep Artham; Steffi Oesterreich; Rinath Jeselsohn; Myles Brown; Sarah Sammons; Suzanne E Wardell; Ching-Yi Chang; John D Norris; Donald P McDonnell
Journal:  Mol Cancer Ther       Date:  2020-05-07       Impact factor: 6.261

7.  Delayed and persistent ERK1/2 activation is required for 4-hydroxytamoxifen-induced cell death.

Authors:  Jian-Hua Zhou; David V Yu; Jingwei Cheng; David J Shapiro
Journal:  Steroids       Date:  2007-07-07       Impact factor: 2.668

8.  27-hydroxycholesterol is an endogenous selective estrogen receptor modulator.

Authors:  Carolyn D DuSell; Michihisa Umetani; Philip W Shaul; David J Mangelsdorf; Donald P McDonnell
Journal:  Mol Endocrinol       Date:  2007-09-13

Review 9.  Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs).

Authors:  Terry W Moore; Christopher G Mayne; John A Katzenellenbogen
Journal:  Mol Endocrinol       Date:  2009-11-20

10.  Estrogen Regulation of MicroRNA Expression.

Authors:  Carolyn M Klinge
Journal:  Curr Genomics       Date:  2009-05       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.